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carcinomas
M Volm', W Rittgen2 and P Drings3
Departments of 'Oncological Diagnostics and Therapy and 2Biostatistics, German Cancer Research Center, Heidelberg; 3Chest Hospital, Heidelberg-Rohrbach,
Germany
Summary Patients with previously untreated squamous cell lung carcinomas were evaluated to see ifcombining the expression of molecular
and cellular factors with the most important clinical prognostic factors could improve the diagnostic ability to predict prognosis. For this
reason, immunohistochemistry was used to examine the squamous cell lung carcinomas from 121 patients for their expression of ERBB-1,
vascular endothelial growth factor (VEGF), cyclin A, FOS, JUN and MYC. Median survival was shorter for patients with ERBB-1-, VEGF-,
cyclin A-, FOS-, orJUN-positive tumours. Forthose patients with positive lymph node involvement, the survival times were also shorter in the
VEGF-positive, cyclin A-positive and FOS-positive groups. Multivariate analysis independently demonstrated a significant prognostic value
for lymph node involvement, VEGF and FOS.
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In addition to established factors such as the extent of tumour,
lymph node involvement and the particular stage ofthe disease for
lung carcinomas, the search for new risk factors that act indepen-
dently of one another is an ongoing undertaking. Prognostic
factors in cancer serve many purposes: they are used to understand
the natural history of cancer, to identify homogeneous patient
populations, to characterize subsets ofpatients with favourable or
unfavourable outcome, to predict the success oftherapy or to plan
follow-up strategies.
This investigation attempted to prove the relevance of molec-
ular and cellular factors, measured by immunohistochemistry, for
the prognosis of patients with squamous cell lung cancer. The
transformation of a normal bronchoepithelial cell into a fully
malignant cancer is thought to be a step process. A sequence of
separate events leads to an accumulation of genetic damage and
each ofthese events consists ofeither activation or inactivation of
growth regulatory genes and proteins (Moolenaar et al, 1986). The
FOS/JUN complex binds specifically to a DNA sequence referred
to as the AP-1 binding site and thus affects the transcriptional
expression of cellular genes (Sassone-Corsi et al, 1988). MYC is
also involved in transcriptional regulation (Spandidos et al, 1990).
Binding epidermal growth factors to ERBB-1 activates tyrosine
kinase and initiates a signal transduction process (Moolenaar et al,
1986). Furthermore, protein complexes that are composed of
cyclins and cyclin-dependent kinases are important factors in
cellular proliferation (Cordon-Cardo, 1995). A number of studies
reported that high microvessel density was associated with a
greater incidence ofmetastases and reduced patient survival (for a
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review see Weidner, 1995). Considerable evidence now indicates
that tumour cells can produce diffusible angiogenic regulatory
molecules. The current leading candidate is the vascular endothe-
lial growth factor (VEGF).
In the present study, we evaluated whetheror not combining the
expression of the above-mentioned factors with the most impor-
tant clinical prognostic factors can improve the prognostic value
for patients with squamous cell lung carcinomas. To this purpose,
121 patients with squamous cell lung carcinoma had their cancers
analysed using immunohistochemical techniques. The expression
of ERBB1, VEGF, cyclin A, FOS, JUN and MYC were deter-
mined and the results obtained were evaluated along with the
clinical data from the viewpoint ofoverall survival.
MATERIALS AND METHODS
Patients and tumours
Patients with previously untreated squamous cell lung carcinomas
(n = 121) were admitted into this study. They hadreceived surgical
treatment in the Chest Hospital Heidelberg-Rohrbach (Director,
Professor Dr I Vogt-Moykopf) between 1980 and 1983. The
morphological classification of the carcinomas was conducted
according to the WHO study (1981). Tumour classifications were
carried out by two pathologists. According to the guidelines ofthe
American Joint Committee on Cancer (Carr and Mountain, 1977),
all patients were staged at the time of their surgery. Of the 121
patients, 23 had stage I, 10 had stage II and 88 had stage III
tumours. The USCC classification from 1987 was not used
because the patients had been operated on previously. A restaging
according to the new guidelines was not possible, because not all
the criteria for tumour staging were definitive. The patients (113
men and 8 women) ranged in age from 37 to 75 years (mean 58
years). Fifty-one patients did not have lymph node status, whereas
70 patients did. Ninety-four patients were treated by surgical
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Figure 1 Typical immunocytochemical staining of the proteins ERBB-1 (A), VEGF (B), and MYC (C)
Table 1 Median survival times (MST) of patients with squamous cell lung
carcinomas according to clinical varables (n = 121)
Clinical Patients MST Log-rank test Relative
variables (n) (weeks) P-value risk
Total 121 107 - -
Age
<58 66 92 NS (0.51) 1.0
>58 55 111 1.2
Sex
Male 113 108 NS (0.09) 1.0
Female 8 38 1.9
Tumour extent
T 1,2 38 128 0.026 1.0
T3 83 85 1.9
Lymph node involvement
Negative 51 165 0.024 1.0
Positive 70 68 1.7
Stage
I,'l 33 128 NS (0.06) 1.0
Ill 88 85 1.7
NS, not significant.
Table 2 Median survival times (MST) of patients with squamous cell lung
carcinomas according to cellularfactors (n = 121)
Variables Patients MST Log-rank test Relative
(n) (weeks) P-value risk
ERBB-1
Negative 21 > 260 0.018 1.0
Positive 100 92 2.3
VEGF
Negative 97 117 0.006 1.0
Positive 12 47 2.3
cyclin A
Negative 29 > 260 0.028 1.0
Positive 78 87 1.9
FOS
Negative 49 > 260 0.009 1.0
Positive 72 92 1.9
JUN
Negative 69 117 0.029 1.0
Positive 51 84 1.6
MYC
Negative 62 102 NS (0.9) -
Positive 59 112
Tumour matenal was not available forall measurements (missing data: JUN
one; cyclin A 14; VEGF, 12).
procedures only and 27 patients received palliative irradiation.
The additional radiation treatment had no significant effect on
patient survival time. Follow-up data were obtained from hospital
charts and by corresponding with the referring physicians.
Survival times were determined from the day of surgery. Eight
patients who died within 4 weeks after surgery were excluded
from the analysis.
Immunohistochemistry
The previously described biotin-streptavidin method (Volm et al,
1988; 1993) was used to detect FOS, JUN, MYC, ERBB-1, cyclin
A and VEGF. To detect the c-fos gene product we used the rabbit
polyclonal antibody c-fos Ab-2 (Dianova, Hamburg, Germany).
This antibody was developed against a peptide corresponding to
residues 4-17 ofhuman FOS. Thec-jun geneproduct was detected
by the rabbit polyclonal antibody c-jun/AP-l (Ab-1, Dianova).
This antibody was developed against a peptide corresponding to
the amino acids 209 to 225 in the DNA binding domain ofv-jun,
C-terminal region. To detect the c-myc product the mouse mono-
clonal antibody c-myc (Ab-3, Dianova) was applied. The rabbit
polyclonal antibody EGFR (Ab-4, Dianova) was used to detect the
gene product of c-erbB-1. This antibody was raised against a
peptide corresponding to the amino acid residues 1005 to 1016 of
EGFR. For staining ofVEGF, a rabbit polyclonal anti-VEGF anti-
body (Ab-2, Dianova) was used. Staining for cyclin A protein
was undertaken with a rabbit polyclonal antibody (cyclin A,
H-432, Santa Cruz Biotechnology, Heidelberg, Germany) that
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Figure 2 Kaplan-Meler estimates of patient survival in cases of squamous cell lung carcinomas (total n = 121 patients). Additional assessments are presented
according to tumour extent (T), lymph node involvement (LN) and the expression of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC
corresponded to amino acids 1-423 and represented full-length
human cyclin A.
Formnalin-fixed and paraffin-embedded tumour sections were
deparaffi'nized according to standard histological procedures.
After preincubation with hydrogen peroxide (0.3%), saponin
(0.05%), unlabelled streptavidin and non-immunized normal
serum (1:10, 15 min), the primary antibodies were applied for 16 h
at 4"C in a moist chamber. This antibody application occurred at a
concentration between and 10 gig ml'. The most appropriate
concentration was determined in preliminary experiments. After
washing three times with phosphate-buffered saline (PBS), the
sections were incubated for 45 min at room temperature in the
presence of biotinylated goat anti-rabbit Ig or sheep anti-mouse Ig
(1:50) as a secondary antibody (both with 5% normal human
serum). Thereupon, the streptavidin biotinylated peroxidase
complex (Amersham, Braunschweig, Germany; dilution 1:100,
15 min) was added. After washing three times with PBS and incu-
bation in 0.5% Triton X-100 (30 s), the peroxidase activity was
made visible with 3-amino-9-ethylcarbazole (15 min). Counter-
staining was performed with haematoxylin. Negative controls
were prepared by omitting the primary antibodies and by substi-
tuting irrelevant antibodies for the primary antibodies.
The immunohistochemical staining was analysed according to a
scoring method previously validated by us in a series of animal
and human cell lines and human solid tumours. Without having
any previous knowledge of each patient's clinical data, three
observers independently evaluated the results from the staining
procedure. The evaluations agreed in 90% of the samples. The
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Table 3 Relationship between lymph node involvement (LN) and cellular
factors
Variables LN-negative LN-positive P-value
ERBB-1
Negative 10 11 NS (0.57)
Positive 41 59
VEGF
Negative 40 57 NS (0.60)
Positive 4 8
cyclin A
Negative 14 15 NS (0.30)
Positive 29 49
FOS
Negative 21 28 NS (0.90)
Positive 30 42
JUN
Negative 35 34 0.019
Positive 15 36
Table 4 Median survival times (MST) of the subgroup of patients with
squamous cell lung carcinomas and positive lymph node status (n = 70)
subdivided according to the expression of cellular factors
Variables Patients MST Log-rank test Relative
(n) (weeks) P-value risk
ERBB-1
Negative 11 43 NS (0.61) -
Positive 59 69
VEGF
Negative 57 88 0.005 1.0
Positive 8 28 2.8
cyclin A
Negative 15 > 260 0.027 1.0
Positive 49 57 2.5
FOS
Negative 28 128 0.008 1.0
Positive 42 47 2.2
remaining specimens (10%) were independently re-evaluated and
then categorized according to the classification made most
frequently by the observers.
To assess the protein expression, a score corresponding to the
sum of(a) the percentage ofpositive cells (0 = no immunopositive
cells; 1 = < 25% positive cells; 2 = 26-50% positive cells; and 3 =
> 50% positive cells) and (b) the staining intensity (0 = negative;
1 = weak; 2 = moderate; 3 = high) was established. Tumours were
classified as negative for FOS, JUN, MYC and cyclin A when
staining was completely absent and were deemed positive when
the above-mentioned factors attained a cumulative score from 2 to
6 (score 1 is impossible). Tumours were graded as VEGF negative
and ERBB1 negative when they yielded a score between 0 and 2
compared with the baseline value. In these cases, tumours with
scores of3 and 4 were classified as weakly positive and those with
scores of5 and 6 as strongly positive.
ERBB-1 was detected at the cell membrane (Figure IA); VEGF
was found distributed in the cytoplasm (Figure IB); cyclin A
exhibited both cytoplasmic and nuclear immunoreactivity; MYC
(Figure IC), FOS and JUN were expressed in the nucleus.
Statistical analysis
Patient survival time was determined from the date ofsurgery until
the last follow-up visit or reported death, and was evaluated by
using life table analyses according to the method of Kaplan and
Meier. Groups were compared using long-rank tests (Kalbfleisch
and Prentice, 1980). The prognostic influence of clinical and
molecular parameters was examined by multivariate regression
methods (Cox model) (see Kalbfleisch and Prentice, 1980). A
variable selection strategy was used similar to that described by
Byar (1982). The correlations between clinical and molecular
parameters were statistically evaluated by using Fisher's exact test
(Fleiss, 1973). Throughout this paper a P-value of <0.05 is
considered to be statistically significant.
RESULTS
The purpose of the analysis was to ascertain whether or not
combining the expression of molecular and cellular factors with
clinical prognostic factors can yield improved prognostic value for
patients with squamous cell lung carcinomas.
The overall prognosis ofpatients with squamous cell lung carci-
nomas is mainly determined by tumour extent (T) and lymph node
involvement (LN). This holds true for our group ofpatients (Table
1). Patients with T3 tumors and positive lymph nodes (LN) had
significantly shorter survival times (T, P = 0.026; LN, P = 0.024).
The median survival time for patients with Tl or T2 tumours was
128 weeks and for patients with T3 tumours, only 85 weeks. The
relative risk estimate for patients with T3 tumours was 1.9 when
compared with patients with TI or T2 tumours. Patients without
any lymph node involvement had median survival times of 165
weeks. With lymph node involvement this decreased to 68 weeks.
The relative risk estimates forpatients with a positive lymph node
status was 1.7. Stage and sex exhibited only a borderline signifi-
cance; age had no effect on survival.
To discover new cellular prognostic factors in addition to
tumour extent and lymph node involvement, the expression of
several molecular and cellular factors was analysed (Table 2). Of
the 121 squamous cell lung carcinomas, 21 (17%) did not show
ERBB-l expression, whereas 100 (83%) showedpositive staining.
The median survival was shorter for patients with ERBB-1-posi-
tive tumours than for those with ERBB1-negative tumours (92 vs
> 260 weeks; P = 0.018). The relative risk estimate for those
patients was increased by a factor of 2.3. High VEGF expression
was found in 12 instances (11%), whereas 97 cases (89%) did not
express VEGF or demonstrated only moderate expression.
Patients with VEGF-positive tumour cells had significantly lower
median survival times (47 vs 117 weeks) than patients with nega-
tive or only moderately stained cells (P = 0.006). The survival
times were significantly shorter in patients with cyclin A-positive
tumours than in patients with cyclin A-negative tumours
(87 vs > 260 weeks, P = 0.028).
A total of 72 out of 121 (60%) squamous cell lung carcinomas
were positive forFOS; 51 out of 120 (43%) were positive forJUN;
59 out of 121 (49%) were positive for MYC. Median survival
times were significantly shorter for patients with FOS positive (92
vs > 260 weeks; P = 0.009) and with JUN positive (84 vs 117
weeks; P = 0.029) carcinomas (Table 2). The expression of MYC
in squamous cell lung carcinomas showed no significant correla-
tion with survival. Furthermore, other assorted parameters (e.g.
RAS, ERBB-2) had no significant correlation with survival (data
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not shown). Figure 2 shows the survival curves (Kaplan-Meier
estimates) ofpatients forming subgroups according to clinical and
cellular factors.
A significant relationship between tumour extent (T) and the
factors ERBB-1, VEGF, cyclin A, FOS and JUN was not observed
(data not shown). ERBB-1, VEGF, cyclin A and FOS also acted
independently of lymph node involvement for the patient popula-
tion examined here (Table 3). However, JUN was expressed to a
significantly higher frequency in patients with positive lymph
node involvement (P = 0.019; Table 3).
The factors ERBB-1, VEGF, cyclin A and JUN presented no
inter-relationships or interdependencies. Only the presence of
FOS was strongly correlated with ERBB-1 (P = 0.001), VEGF
(P = 0.02), and JUN (P = 0.0009) being positive.
To ascertain whetherthe expression ofERBB-1, VEGF, cyclin A
and FOS can add prognostic information to the important clinical
factors, we determined the median survival ofpatients withpositive
lymph node involvement and the corresponding dependence upon
the expression or non-expression of these factors (Table 4). In this
analysis, survival times were also shorter in the VEGF-positive,
cyclin A-positive and FOS-positive groups ofpatients. For patients
with VEGF-negative carcinomas the median survival time was 88
weeks and for patients with VEGF-positive carcinomas only 28
weeks (P = 0.005). The corresponding values forcyclin A and FOS
were > 260 vs 57 weeks (P = 0.027) and 128 vs 47 weeks (P =
0.008) respectively. Figure 3 shows the survival curves (Kaplan-
Meier estimates) for patients with positive lymph node status
according to the expression of VEGF, cyclin A and FOS. It can
clearly be seen that the prognostic value can be improved by
combining clinical and cellular or molecular parameters.
In addition to descriptively evaluating the prognostic relevance
of the identified clinical and cellular factors as mentioned above,
we also analysed the data from the 121 squamous cell carcinoma
patients using the proportional hazards regression model (Cox
model). The factors were introduced into a multivariate regression
analysis that consisted of several consecutive steps as follows:
lymph node involvement and tumour extent were significant prog-
nostic clinical factors obtained from the univariate analysis. As
both factors were highly correlated, only one factor could be
simultaneously included in a multivariate analysis. Reported next
Table 5 Bivariate analysis of the prognostic value exhibited by the cellular
parameters that had shown an effect upon the survival time during univariate
analysis (Table 2) and lymph node involvement (LN)
Beta RR P-value
LN 0.69 2.0 0.008
VEGF 0.95 2.6 0.003
LN 0.47 1.6 0.05
ERBB-1 0.79 2.2 0.04
LN 0.57 1.8 0.02
FOS 0.67 2.0 0.007
LN 0.48 1.6 0.06
cyclin A 0.64 1.9 0.04
RR, relative risk.
are the results obtained using lymph node involvement as the only
classical factor (negative vs positive). Based upon the immunohis-
tochemistry parameters, we had to consider VEGF, ERBB-1, FOS
and cyclin A as possible candidates for a multivariate analysis,
because they had shown a significant prognostic value in the
univariate analysis. JUN was not included because of its positive
correlation with lymph node involvement and other cellular para-
meters such as FOS. Next, we investigated separately VEGF,
ERBB1, FOS and cyclin A for their prognostic value when
combined with lymph node involvement (LN). Table 5 shows that
VEGF and FOS demonstrated the strongest prognostic influence
(P = 0.003 and P = 0.007) independent ofLN, whereas, the effect
of ERBB-1 and cyclin A was just barely significant (P = 0.04).
When comparing the relative risk ofpatients with positive lymph
nodes (LN) or patients with positive cellular parameters, we found
a relative risk over baseline between 1.6 and 2.6. It was highest in
the analysis of LN together combined with VEGF (2.0 and 2.6).
The next highest risks were observed in the analysis of LN
together with FOS (1.8 and 2.0). This indicates that good prog-
nostic differentiation can be achieved by using LN combined with
VEGF. To a somewhat smaller extent, it is also possible to use LN
and FOS. The parameters ERBB-1 and cyclin A yielded a lower
prognostic value.
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Figure 3 Kaplan-Meier estimates of patient survival in individuals having squamous cell lung carcinomas accompanied by a positive lymph node status and
according to the expression of VEGF, cyclin A and FOS
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Table 6 Multivariate analysis of the prognostic value of all five factors (a)
and of the two most important ones (LN and VEGF) combined with one of the
remaining factors for the survival time (b-d)
Beta RR P-value
(a) LN 0.65 1.9 0.02
VEGF 0.64 1.9 0.04
FOS 0.40 1.5 0.17
cyclin A 0.37 1.5 0.28
ERBB-1 0.23 1.3 0.47
(b) LN 0.71 2.0 0.006
VEGF 0.77 2.2 0.02
FOS 0.61 1.8 0.03
(c) LN 0.65 1.9 0.02
VEGF 0.80 2.2 0.02
cyclin A 0.45 1.6 0.18
(d) LN 0.66 1.9 0.01
VEGF 0.80 2.2 0.02
ERBB1 0.51 1.7 0.09
RR, relative risk.
Table 7 Multivariate analysis of the prognostic value of tumour size as
described by T (a) or stage (b) and the cellular parameters for the overall
survival
Beta RR P-value
(a) T 0.49 1.6 0.08
VEGF 0.60 1.8 0.07
FOS 0.52 1.7 0.06
(b) Stage 0.45 1.6 0.13
VEGF 0.58 1.8 0.08
FOS 0.57 1.8 0.04
RR, relative risk.
A multivariate analysis ofall five factors indicated that LN and
VEGF were the most important factors (P = 0.02 and P = 0.08,
Table 6a). The relative risk estimates of positive LN and positive
VEGF were 1.9. When we simplified the multivariate model and
only used LN, VEGF and FOS, all three parameters showed a
significant prognostic value (Table 6b). When we analysed LN,
VEGF, and cyclin A (Table 6c) or LN, VEGF and ERBB-l only
LN and VEGF were significant (Table 6d).
Next we examined separately the prognostic influence of the
cellular parameters in the two LN strata (positive or negative).
None of the four cellular parameters demonstrated any significant
influence in the subgroup of patients (n = 38) that could be evalu-
ated and that had negative LN in the multivariate analysis
(P > 0.2). In the subgroup ofpatients (n = 68) that could be evalu-
ated and that had positive nodes, VEGF was the sole significant
factor (P = 0.04). FOS tended to exert some influence (P = 0.13).
When using VEGF as the only factor to explain the variation
of the survival times, it was clearly significant (P = 0.02) in
that subgroup and yielded a relative risk estimate of 2.7. These
findings were confirmed by a Cox model using LN as the stratum
variable. In this instance, VEGF was the only significant factor
(P = 0.02); it resulted in a relative risk estimate of2.3 using a back-
ward selection procedure. Furthermore, the all subset selection
procedure identified LN as the most important single factor, LN
and VEGF were deemed the most important pair of factors, and
LN, VEGF and FOS were the most important triple offactors.
Retuming to the selection of the clinical variables in which LN
had been clearly selected as the most significant factor, we also
investigated whether or not the selection of cellular factors could
have been influenced by the choice of clinical factors. Therefore,
we analysed VEGF and FOS along with tumour extent and
tumour stage (Table 7). The results confirmed that VEGF and
FOS are important prognostic factors for survival of patients with
squamous cell lung carcinomas.
DISCUSSION
This investigation attempted to prove the prognostic value of
several cellularfactors, measured using immunohistochemistry, of
patients with squamous cell lung cancer. This study clearly shows
that immunohistochemical analysis of cellular factors possesses
independent prognostic significance for patients with squamous
cell lung carcinomas.
As the oncoproteins FOS and JUN co-operate in the activation
oftranscription from specific promoter elements, it is conceivable
that they might also co-operate in inducing a proliferative state
(Auwerx and Sassone-Corsi, 1991). In our analysis, we did indeed
find that (a) FOS and JUN expression is highly correlated and that
(b) patients with FOS- and JUN-positive carcinomas had a poorer
clinical outcome than otherpatients with squamous cell lung carci-
nomas. The c-erbB-1 gene product is also involved in the regula-
tion of cell growth and proliferation (Carney, 1991). In our
investigation we discovered that patients with an expression of
ERBB-1 had shorter survival times. Spandidos et al (1990) exam-
ined MYC expression in specimens of bronchogenic carcinomas
by immunohistochemical means and found that this protoonco-
gene product is important for tumour progression. However, we
could detect no correlation between elevated MYC and patient
survival. Earlier research conducted by us found that MYC was
more frequently expressed in lymph node metastases of patients
with primary lung carcinomas (Volm et al, 1994). In the present
investigation, this result could be confirmed for squamous cell
lung carcinomas. However, we could also show that MYC is not a
prognostic indicator for the survival time of patients with squa-
mous cell lung carcinomas. Other investigated factors (e.g. RAS,
ERBB-2) did not show any association with survival (data not
shown).
Along with other researchers (Dutta et al, 1995; Paterlini et al,
1995), we found that the expression of cyclin A is closely corre-
lated to the proportion of S-phase cells as measured by flow
cytometry (data not shown). Univariate analysis indicates that
cyclin A may also be a good prognostic indicator for the survival
of patients with squamous cell lung carcinomas, but this was no
longer seen in the multivariate analysis.
Tumour angiogenesis is thought to be mediated by different
factors. One such factor is VEGF, a dimeric glycoprotein.
VEGF165, which we analysed, is the most abundant isoform
(Ferrara et al, 1992). Toi et al (1994) found that the relapse-free
survival rate of patients with VEGF-rich breast carcinomas was
significantly worse than that ofpatients with VEGF-poor tumours.
Similarly, Maeda et al (1996) noted a significantly shorter survival
in patients with VEGF-positive gastric carcinomas than in those
having VEGF-negative tumours. Those data and our own indicate
that VEGF expression may be an additional prognostic indicator.
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In addition to evaluating the prognostic relevance ofthe cellular
factors descriptively, we analysed the data using the proportional
hazards regression model (Cox model). In our analysis, VEGF and
FOS revealed the strongest prognostic influence on survival, inde-
pendent of lymph node involvement. The other cellular factors
(ERBB-I and cyclin A) were only ofborderline significance.
In addition, we examined whether the selection of the cellular
factors could have been influenced by the choice of clinical para-
meters. Therefore, we also analysed the cellular factors along with
tumour extent and tumour stage. The results with tumour extent
and tumour stage confirmed the data obtained with lymph node
involvement.
In this study, we found that in addition to the very important
factoroflymph node involvement othercellularparameters (VEGF,
FOS) also serve as prognostic factors of the patient's clinical
outcome in squamous cell lung carcinomas. These supplemental
prognostic factors are readily available at an acceptable cost.
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